Apr 1, 2020
FITT Akza through micelle-technology aims to enhance ARVIDAL efficacy to combat Covid-19
Jakarta, Apr 1, 2020 (Issuewire.com) - PT. FITT Akza Internasional (FITT Akza) and PVP Labs Pte. Ltd. (PVP) have mutually agreed to cooperate by signing a memorandum of understanding (MoU) concerning the "research, development and enhancement of PVP existing Prophylactic Products", which addresses the prevention and treatment of Acute Respiratory Viral Infection (ARVI) and Acute Respiratory Infections (ARI), covering coronavirus including the COVID-19 strand, influenza, including other common pathogens and infections of unknown origin.
With the current COVID-19 pandemic, there is an urgent need for available prevention and/or treatment to address the widespread global infection. As the death toll increases and the virus continues to spread, many governments have imposed countrywide lockdowns to contain the virus. The social burden of the pandemic is mostly characterised by high indirect costs, such as costs for the period of lockdown and workplace absence, economic losses due to reduced labour productivity, and costs of resources in addressing the pandemic, including the costs of lockdown enforcement.
The MoU is a form of mutual commitment in complementing each other's duties and functions from the perspective of research and development. As part of the MoU, PVP will work with Swiss PharmaCan AG (https://www.swisspharmacan.ch/), a major shareholder of FITT Akza to further improve the efficiency and quality of development of "ARVIDAL" (PVP Labs Pte Ltd, assignee. Antiviral Immunotropic Agent for the Treatment of Acute Respiratory Viral Infections. Patent Application No. US 20190322701 (2018 Dec 15), EP 3556377 A1, WO 2019202380, RU 2672888).
Based in Switzerland, Swiss PharmaCan AG and MiVital AG's latest developed technology, namely MyCell Enhanced is a unique, award-winning and patented micelle-technology used for the enhancement and production of biopharmaceutical products with optimal bioavailability.
Established in 2019, PT. FITT Akza Internasional is comprised of a group of companies consisting of international financial service providers, and biotechnology companies. FITT Akza aims to assist in providing financing for sustainable projects in Asia, mainly catering to public listed companies or companies which are currently operating with proven track records.
PVP Labs Pte. Ltd. is a Singapore based biotechnology company that specializes in the development of innovative peptide drugs. Since 2010, PVP addresses the needs of major market segments worldwide and distinguishes itself from most biotech companies as the initial research and development are conducted in Russia. The reasons are historical and are substantiated by the quality and extent of existing research that has taken place over many decades, which continues today.
For more information on the MOU, please contact Sedona Development Fund (www.sedona.fund) at email@example.com.
Sedona Development Fund Limited
Penthouse, Centrepoint South,Mid Valley City, Lingkaran Syed Putra,
Source :PT. FITT Akza Internasional
This article was originally published by IssueWire. Read the original article here.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.